- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02730793
Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is designed to explore the efficacy and safety of nasal aztreonam administered using the Pari Sinus Nebulizer combined with oral Cayston aerosol therapy compared to placebo on clinical and laboratory endpoints such as risk of antibiotic-resistant Pseudomonas aeruginosa (PA), time to pulmonary infection exacerbation, nasal quality of life, pulmonary function, nasal and lower airway cultures, and properties of mucus.
P. aeruginosa (PA) is a primary cause of lung infections in persons with cystic fibrosis (CF) (1). Over the past decade, studies have shown that aerosolized antibiotics can reduce lower respiratory bacterial load, decrease exacerbations of pulmonary disease, and in many patients improve pulmonary function. Cayston (aztreonam) oral aerosol using the PARI Altera Nebulizer System was approved by the FDA in February 2010 for CF patients 7 years of age or older with PA (2). In 2011, 35.8% or patients in the National CF Patient Registry used Cayston for treatment (3). Bacterial cultures suggest that the upper airways and lower airways of CF patients are cross-infected by PA and that the paranasal sinuses can act as a bacterial reservoir (4). There is improved post-transplanation patient survival for recipients that undergo sinus surgery and daily nasal washes to reduce bacterial load (2).
Routine CF care does not generally include upper airway assessment. There are no published studies evaluating the effect of aerosol antibiotics to treat nasal and sinus infections in CF in combination with oral inhaled aerosol therapy to treat the lower airway disease. However Mainz and colleagues published a case report that suggested that sinonasal administration of tobramycin using the Pari Sinus nebulizer (Pari Corp, Starnberg, Germany) delayed PA lower respiratory infection in a 12 year-old with CF who had chronic mucopurulent rhinosinusitis (5) and studies in chronic obstructive pulmonary disease suggest that treating upper airways can also improve coexistent lower airway disease.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Children's Hospital of Richmond at VCU
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males or females 7 years of age or older and able to perform pulmonary function testing
- Confirmed diagnosis of CF by the 1997 CF Consensus Conference criteria and followed by the VCU or EVMS CF clinic
- Presence of PA in 2 lower respiratory tract (sputum) cultures in the 24 months before screening
- Subjects and/or parent guardian must be able to give written informed consent prior to any study related procedure
- All sexually active female subjects who are of childbearing potential must agree to use an effective method of contraception (i.e.condoms or abstinence).
- All sexually active female subjects must have a negative pregnancy test at screening (V0).
- Clinically stable determined by the study physician with no significant new respiratory symptoms.
- Presence of PA in nasal culture (swab or secretion) or sinus culture obtained in the 12 months before screening or at screening visit
Exclusion Criteria:
- Use of oral, IV or inhaled antibiotics within 0 days before study other than low dose azithromycin
- Severe pulmonary disease with FEV1<30% predicted of baseline SpO2<0.90
- ENT surgery within 6 months of screening
- Allergy or documented adverse reaction to aztreonam
- Epistaxis or significant (>30mL) hemoptysis in the past 6 months
- Frequent (weekly or more frequently) or severe headaches
- Subject is unlikely to comply with the procedures scheduled in the protocol
- Subject participates in another clinical trial within 30 days prior to study entry
- Subjects who have had a lung transplant will be excluded
- Prisoners will be excluded
- Non-English Speaking patients will be excluded
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard Therapy
Oral Inhalation via PARI Altera Device: Standard Therapy Comparator (Oral Aztreonam 75mg three times a day) AND Nasal Inhalation via PARI PAS Device: Nasal Placebo-Normal Saline twice per day
|
Standard Therapy Comparator (Oral Cayston 75mg three times a day)
Other Names:
Placebo (nasal saline twice per day)
Other Names:
|
Experimental: Study Therapy
Oral Inhalation via PARI Altera Device: Standard Therapy Comparator (Oral Aztreonam 75mg three times a day) AND Nasal Inhalation via PARI PAS Device: Experimental- Nasal Aztreonam 75 mg twice per day
|
Standard Therapy Comparator (Oral Cayston 75mg three times a day)
Other Names:
Study Therapy (nasal Aztreonam 75mg twice per day)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Protocol-defined Pulmonary Exacerbations Treated With IV Anti-pseudomonal Antibiotics on Day 140
Time Frame: 140 days
|
Protocol-Defined Pulmonary Exacerbation includes events that are characterized by change or worsening pulmonary symptoms (increased cough, increased sputum production and chest congestion, decreased appetite and exercise tolerance), loss of weight, and lung function decline that prompt initation of antibiotic therapy.
Protocol-defined exacerbations in subjects that warrant treatment with IV antibiotics will be determined from the medical record during the course of this study.
|
140 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to First Protocol-defined Pulmonary Exacerbation Treated With IV Anti-pseudomonal Antibiotics
Time Frame: Up to 6 months
|
Protocol-Defined Pulmonary Exacerbation includes events that are characterized by change or worsening pulmonary symptoms (increased cough, increased sputum production and chest congestion, decreased appetite and exercise tolerance), loss of weight, and lung function decline that prompt initation of antibiotic therapy.
Protocol-defined exacerbations in subjects that warrant treatment with IV antibiotics will be determined from the medical record during the course of this study.
The time of beginning the study to first protocol-defined pulmonary exacerbation will also be determined from the medical record during the course of this study.
|
Up to 6 months
|
Change in Sinus and Nasal QoL Questionnaire (SNOT-20) on Day 140 and Day 168
Time Frame: Day 140 and Day 168
|
The Sino-Nasal Outcome Test 20 (SNOT-20) is a validated health-related QOL questionnarie designed to determine the impact of sinonasal dysfunction.
Patients will assess nasal symptoms, emotion, and activity on a scale of worsening symptoms scored 1 through 7 to provide a quantifiable score capable of disease severity.
It has been shown as a responsive measure of health-related quality of life and suitable for use in outcomes studies and routine clinical care.
Survey responses from Day 140 and Day 168 will be compared to the SNOT20 survey responses from previous visits (V1, V2, and V4)
|
Day 140 and Day 168
|
Change in Cystic Fibrosis QoL Score (CFQ-R) on Day 140
Time Frame: Day 140
|
The CFQ-R is a validated patient-reported outcome measuring health-related quality of life for children and adults with CF.
The CFQ-R contains both general and CF-specific scales.
The CFQ-R was administered at Visits 1, 6, and 7.
The endpoint was change in CFQR on day 140 compared to V1 and V5.
|
Day 140
|
Change in Pulmonary Function (FVC and FEV1 Percent Predicted) on Day 140
Time Frame: Day 140
|
Routine spirometry will be performed according to American Thoracic Society (ATS) guidelines.
A minimum of three maneuvers will be performed.
The largest FVC and FEV1 will be reported after examining data from all acceptable curves even if they did not originate from the same maneuver.
Data will be expressed both in absolute values and as percent (%) predicted based upon NHANES predicted values.
|
Day 140
|
Change in Paired Sputum Cultures and Nasal Swabs for Bacteria and Antibiotic Resistance
Time Frame: 1 year
|
Expectorated sputum and nasal swabs will be cultured at each visit using standardized procedures to identify CF pathogens as well as susceptibility to a standard panel of antibiotics.
|
1 year
|
Change in Acoustic Rhinometry for Nasal Obstruction (Volume) (Will be Measured at VCU Site ).
Time Frame: 1 year
|
Acoustic rhinometry is used to measure cross-sectional volume of the nasal cavity allowing the calculation of nasal volume.
Reflected sound waves are painlessly introduced through nasal adaptors into the nasal passages allowing the production of area-distance graphs.
|
1 year
|
Number of Safety and Adverse Events Including Nasal Stuffiness, Epistaxis, and Headache.
Time Frame: 1 year
|
The frequency, severity and duration of all nasal and pulmonary adverse events, regardless of cause, will be recorded in REDCap as an electronic case report form.
Serious adverse events will be captured in OnCore.
The frequency and severity of adverse events will be calculated for each patient, with each patient counted once using the most severe grade experienced.
The duration of adverse events will be calculated by the number of days each event persisted.
Tables will be generated for all adverse events including serious adverse events and withdraws from the study.
|
1 year
|
Number of Protocol-defined Pulmonary Exacerbations Treated With Oral Anti-pseudomonal Antibiotics
Time Frame: 1 year
|
Protocol-Defined Pulmonary Exacerbation includes events that are characterized by change or worsening pulmonary symptoms (increased cough, increased sputum production and chest congestion, decreased appetite and exercise tolerance), loss of weight, and lung function decline that prompt initation of antibiotic therapy.
Protocol-defined exacerbations in subjects that warrant treatment with oral antibiotics will be determined from the medical record during the course of this study.
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Bruce K Rubin, MD, Virginia Commonwealth University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HM20005657
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University of Colorado, DenverCystic Fibrosis FoundationTerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in ChildrenUnited States
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaboratorsActive, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver DiseaseUnited Kingdom, Ireland
-
Herlev and Gentofte HospitalCopenhagen University Hospital, DenmarkActive, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of Pancreas | Cystic Fibrosis, Pulmonary | Cystic...Denmark
-
The Hospital for Sick ChildrenCanadian Cystic Fibrosis FoundationActive, not recruitingCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in ChildrenCanada
-
Arrowhead PharmaceuticalsTerminatedCystic Fibrosis, PulmonaryAustralia, New Zealand
-
AzurRx SASCompletedCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of PancreasTurkey, Hungary
-
Dartmouth-Hitchcock Medical CenterTrustees of Dartmouth CollegeWithdrawnCystic Fibrosis-related Diabetes | Cystic Fibrosis Liver Disease | CF - Cystic FibrosisUnited States
-
University Hospital, BordeauxCompleted
-
University of PortsmouthUniversity Hospital Southampton NHS Foundation Trust; Loughborough University; Queen Alexandra HospitalTerminated
Clinical Trials on Oral Aztreonam
-
UCSF Benioff Children's Hospital OaklandGilead SciencesTerminatedTracheostomy InfectionUnited States
-
Gilead SciencesApproved for marketingCystic Fibrosis | Pseudomonas AeruginosaCanada
-
Gilead SciencesSalus Pharma, Inc.CompletedCystic Fibrosis | Pseudomonas Aeruginosa | Lung Infection | CFUnited States
-
Gilead SciencesApproved for marketingCystic Fibrosis | Pseudomonas Aeruginosa Airway InfectionUnited States, Puerto Rico
-
Qianfoshan HospitalRecruitingCarbapenem-Resistant Enterobacteriaceae InfectionChina
-
Melinta Therapeutics, Inc.CompletedSkin and Subcutaneous Tissue Bacterial Infections | Skin Structures and Soft Tissue InfectionsUnited States, Argentina, Brazil, Bulgaria, Chile, Estonia, Georgia, Hungary, Korea, Republic of, Latvia, Mexico, Moldova, Republic of, Peru, Romania, Slovakia, Taiwan
-
PfizerCompletedBacterial Infections | Complicated InfectionUnited Kingdom
-
University of DundeeGilead SciencesRecruitingBronchiectasis AdultUnited Kingdom
-
Gilead SciencesCovance; ClinPhone, Inc.; Chiltern International Inc.CompletedCystic FibrosisBelgium, France, Germany, Italy, Netherlands, Spain, United States, Ireland, United Kingdom, Portugal, Austria, Denmark, Switzerland
-
Gilead SciencesCompletedCystic FibrosisUnited States, France, Spain, Germany, Austria, Belgium, Italy, Netherlands, Poland